Moreover, mutations that trigger resistance to FLT3 inhibitors can be identified in AML cases including emergence of leukemic clones harboring mutations that activate RAS/MAPK pathway signaling (37). This evidence concerns the gene FLT3 and acute myeloid leukemia.